SCHEMBL5760587

SCHEMBL5760587

Cc1ccc(C(=O)NCc2ccc(N3CCOCC3)cc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.70
KLKB1 P03952 2/20 0.51
KLK1 P06870 2/20 0.51
CCR1 P32246 3/20 0.48
EZH2 Q15910 1/20 0.47
POLB P06746 1/20 0.46
PSMD14 O00487 1/20 0.46
RAF1 P04049 2/20 0.44
BRAF P15056 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759114 0.88 ELANE (0.74) ELANEPOLBMEN1KMT2AALDH1A1
SCHEMBL5758770 0.87 ELANE (0.80) ELANECCR1POLBMEN1KMT2A
SCHEMBL5757209 0.86 ELANE (0.79) ELANECCR1MEN1KMT2AKDM4E
SCHEMBL5756606 0.86 ELANE (0.79) ELANECCR1KDM4EALDH1A1RECQL
SCHEMBL5755788 0.86 ELANE (0.79) ELANECCR1POLBKDM4EALDH1A1
SCHEMBL5756979 0.85 ELANE (0.78) ELANECCR1KDM4EALDH1A1RECQL
SCHEMBL5756834 0.85 ELANE (0.78) ELANECCR1MEN1KMT2AALDH1A1
SCHEMBL5759291 0.85 ELANE (0.78) ELANECCR1KDM4EALDH1A1RECQL
SCHEMBL6195065 0.84 ELANE (0.68) ELANEPOLBMEN1KMT2AALDH1A1
SCHEMBL5758008 0.84 ELANE (0.68) ELANECCR1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885KLKB1 262/4885KLK1 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.